Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro interactions of approved and novel drugs against Paecilomyces spp.

Literature DB >> 15215136

In vitro interactions of approved and novel drugs against Paecilomyces spp.

Montserrat Ortoneda¹, Javier Capilla, F Javier Pastor, Isabel Pujol, Clara Yustes, Carolina Serena, Josep Guarro.

Abstract

We have evaluated the in vitro activity of 15 combinations of antifungal drugs (amphotericin B, itraconazole, voriconazole, albaconazole, ravuconazole, terbinafine, and micafungin) against four isolates of Paecilomyces variotii and three of P. lilacinus. The interaction of terbinafine with the four azoles was synergistic for 53% of the combinations, while the interactions of both amphotericin B and micafungin with the rest of antifungal agents were mainly indifferent.

Entities: Chemical Species

Mesh：

Substances：

Year: 2004 PMID： 15215136 PMCID： PMC434163 DOI： 10.1128/AAC.48.7.2727-2729.2004

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

12 in total

1. Paecilomyces lilacinus infection in a heart transplant recipient and successful treatment with terbinafine.

Authors: N M Clark
Journal: Clin Infect Dis Date: 1999-05 Impact factor: 9.079

2. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species.

Authors: N S Ryder; I Leitner
Journal: Med Mycol Date: 2001-02 Impact factor: 4.076

Review 3. Echinocandin antifungal drugs.

Authors: David W Denning
Journal: Lancet Date: 2003-10-04 Impact factor: 79.321

Review 4. Hyalohyphomycosis by Paecilomyces lilacinus in a renal transplant patient and a review of human Paecilomyces species infections.

Authors: L G Castro; A Salebian; M N Sotto
Journal: J Med Vet Mycol Date: 1990

Review 5. Cutaneous manifestations of Paecilomyces lilacinus infection induced by a contaminated skin lotion in patients who are severely immunosuppressed.

Authors: P H Itin; R Frei; S Lautenschlager; S A Buechner; C Surber; A Gratwohl; A F Widmer
Journal: J Am Acad Dermatol Date: 1998-09 Impact factor: 11.527

6. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi.

Authors: J Capilla; M Ortoneda; F J Pastor; J Guarro
Journal: Antimicrob Agents Chemother Date: 2001-09 Impact factor: 5.191

7. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study.

Authors: A Espinel-Ingroff; V Chaturvedi; A Fothergill; M G Rinaldi
Journal: J Clin Microbiol Date: 2002-10 Impact factor: 5.948

Review 8. Complicated soft tissue infection with prepatellar bursitis caused by Paecilomyces lilacinus in an immunocompetent host: case report and review.

Authors: F Westenfeld; W K Alston; W C Winn
Journal: J Clin Microbiol Date: 1996-06 Impact factor: 5.948

9. Antifungal susceptibilities of Paecilomyces species.

Authors: C Aguilar; I Pujol; J Sala; J Guarro
Journal: Antimicrob Agents Chemother Date: 1998-07 Impact factor: 5.191

10. Physiologically based pharmacokinetic model for terbinafine in rats and humans.

Authors: Mahboubeh Hosseini-Yeganeh; Andrew J McLachlan
Journal: Antimicrob Agents Chemother Date: 2002-07 Impact factor: 5.191

12 in total

1. Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus successfully treated by oral voriconazole and nystatin packing.

Authors: Ching-Yu Huang; Pei-Lun Sun; Hsiang-Kuang Tseng
Journal: Mycopathologia Date: 2011-03-20 Impact factor: 2.574

2. A case of indolent endocarditis.

Authors: Hanane Benbarkat; Karima Addetia; Amir H Salehi; Donald Sheppard; Thao Huynh
Journal: Can J Infect Dis Med Microbiol Date: 2012 Impact factor: 2.471

3. Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model.

Authors: Michael J Dolton; Vidya Perera; Lisa G Pont; Andrew J McLachlan
Journal: Antimicrob Agents Chemother Date: 2013-10-14 Impact factor: 5.191

4. In vitro evaluation of the type of interaction obtained by the combination of terbinafine and itraconazole, voriconazole, or amphotericin B against dematiaceous molds.

Authors: Fernanda Simas Corrêa Biancalana; Luzia Lyra; Angélica Zaninelli Schreiber
Journal: Antimicrob Agents Chemother Date: 2011-06-20 Impact factor: 5.191

Review 5. Pulmonary mycetoma caused by an atypical isolate of Paecilomyces species in an immunocompetent individual: case report and literature review of Paecilomyces lung infections.

Authors: F Gutiérrez; M Masiá; J Ramos; M Elía; E Mellado; M Cuenca-Estrella
Journal: Eur J Clin Microbiol Infect Dis Date: 2005-09 Impact factor: 3.267

6. In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus.

Authors: Carolina Serena; Belkys Fernández-Torres; F Javier Pastor; Luciana Trilles; Márcia Dos Santos Lazéra; Nicole Nolard; Josep Guarro
Journal: Antimicrob Agents Chemother Date: 2005-07 Impact factor: 5.191